Molekulargenetische Diagnostik
Praxis Dr. Mato Nagel

Transkriptionsfaktor TFAP2A

Das TFAP2A-Gen kodiert einen Transkriptionsfaktor. Mutationen führen zum Branchio-okulo-faziales Syndrom.

Diagnostik:

Clinic Untersuchungsmethoden Familienuntersuchung
Bearbeitungszeit 5
Probentyp genomic DNA
Research Untersuchungsmethoden Direkte Sequenzierung der proteinkodierenden Bereiche eines Gens
Bearbeitungszeit 25
Probentyp genomic DNA
Clinic Untersuchungsmethoden Hochdurchsatz-Sequenzierung
Bearbeitungszeit 25
Probentyp genomic DNA

Krankheiten:

Branchio-okulo-faziales Syndrom
TFAP2A

Referenzen:

1.

Fielding DW et. al. (1992) Recurrence of orbital cysts in the branchio-oculo-facial syndrome.

[^]
2.

Gaynor RB et. al. (1991) Localization of the gene for the DNA-binding protein AP-2 to human chromosome 6p22.3-pter.

[^]
3.

Mitchell PJ et. al. (1987) Positive and negative regulation of transcription in vitro: enhancer-binding protein AP-2 is inhibited by SV40 T antigen.

[^]
4.

Williams T et. al. (1988) Cloning and expression of AP-2, a cell-type-specific transcription factor that activates inducible enhancer elements.

[^]
5.

Lin AE et. al. (1995) Further delineation of the branchio-oculo-facial syndrome.

[^]
6.

Bauer R et. al. (1994) The genomic structure of the human AP-2 transcription factor.

[^]
7.

Buettner R et. al. (1993) An alternatively spliced mRNA from the AP-2 gene encodes a negative regulator of transcriptional activation by AP-2.

[^]
8.

Schorle H et. al. (1996) Transcription factor AP-2 essential for cranial closure and craniofacial development.

[^]
9.

Zhang J et. al. (1996) Neural tube, skeletal and body wall defects in mice lacking transcription factor AP-2.

[^]
10.

Williamson JA et. al. (1996) Chromosomal mapping of the human and mouse homologues of two new members of the AP-2 family of transcription factors.

[^]
11.

Warren G et. al. (1996) Physical and genetic localization of the gene encoding the AP-2 transcription factor to mouse chromosome 13.

[^]
12.

Davies AF et. al. (1999) An interstitial deletion of 6p24-p25 proximal to the FKHL7 locus and including AP-2alpha that affects anterior eye chamber development.

[^]
13.

Lin AE et. al. (2000) Exclusion of the branchio-oto-renal syndrome locus (EYA1) from patients with branchio-oculo-facial syndrome.

[^]
14.

Zhu CH et. al. (2001) Expression of AP-2 alpha in SV40 immortalized human lung fibroblasts is associated with a distinct pattern of cytosine methylation in the AP-2 alpha promoter.

[^]
15.

Cheng YH et. al. (2003) Identification of an enhancer of the human activating protein-2alpha gene that contains a critical Ets1 binding site.

[^]
16.

Lim JH et. al. (2005) AP-2alpha selectively regulates fragile X mental retardation-1 gene transcription during embryonic development.

[^]
17.

Milunsky JM et. al. (2008) TFAP2A mutations result in branchio-oculo-facial syndrome.

[^]
18.

Tekin M et. al. (2009) A complex TFAP2A allele is associated with branchio-oculo-facial syndrome and inner ear malformation in a deaf child.

[^]
19.

Gestri G et. al. (2009) Reduced TFAP2A function causes variable optic fissure closure and retinal defects and sensitizes eye development to mutations in other morphogenetic regulators.

[^]
20.

Bassett EA et. al. (2010) AP-2alpha knockout mice exhibit optic cup patterning defects and failure of optic stalk morphogenesis.

[^]
21.

Reiber J et. al. (2010) Additional clinical and molecular analyses of TFAP2A in patients with the branchio-oculo-facial syndrome.

[^]
22.

Zarelli VE et. al. (2013) Inhibition of neural crest formation by Kctd15 involves regulation of transcription factor AP-2.

[^]
23.

Montagnac G et. al. (2013) αTAT1 catalyses microtubule acetylation at clathrin-coated pits.

[^]

 

 
Ihre Nachricht: